Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Safety of Subsequent Treatment With [90]Y-Ibritumomab Tiuxetan [ibritumomab tiuxetan Y-90] Versus no Further Treatment in Patients With Stage III or IV Follicular Non-Hodgkin's Lymphoma Having Achieved Partial or Complete Remission After First Line Chemotherapy. A Prospective, Multicenter, Randomized Phase III Clinical Trial

Next Previous
X
Search
Trial Profile

Efficacy and Safety of Subsequent Treatment With [90]Y-Ibritumomab Tiuxetan [ibritumomab tiuxetan Y-90] Versus no Further Treatment in Patients With Stage III or IV Follicular Non-Hodgkin's Lymphoma Having Achieved Partial or Complete Remission After First Line Chemotherapy. A Prospective, Multicenter, Randomized Phase III Clinical Trial

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 23 Jul 2013

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ibritumomab tiuxetan (Primary)
  • Indications Follicular lymphoma
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms FIT
  • Sponsors Bayer HealthCare Pharmaceuticals

    • Most Recent Events

    • 07 Dec 2010 Updated results will be presented at the 52nd American Society of Hematology annual meeting, according to a Spectrum Pharmaceuticals media release.
    • 06 Jul 2009 The US FDA has requested data from the FIT study to validate a subset of data from the supplemental Biologics License Application package for ibritumomab tiuxetan.
    • 28 Nov 2008 Data at a median 42 (2-77) months of follow-up in 409 patients presented at ASH 2008.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top